Oxlumo® (lumasiran) – New orphan drug approval
November 23, 2020 - The FDA announced the approval of Alnylam’s Oxlumo (lumasiran), for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.
Download PDF
